Literature DB >> 25649878

From the 1990s to CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) trial results and beyond: does stenting have a role in ischemic nephropathy?

Maristela Böhlke1, Franklin Correa Barcellos2.   

Abstract

The prevalence of atherosclerotic renal artery stenosis is high, ∼7% in individuals older than 65 years and ∼50% in patients with diffuse arterial disease, and it is increasingly frequent in an aging population. About 10% to 15% of atherosclerotic renal artery stenosis cases lead to the development of resistant hypertension and/or ischemic nephropathy. The management of ischemic nephropathy may include medical therapy and/or revascularization. In the past, revascularization required surgical bypass or endarterectomy, accompanied by the morbidity and mortality associated with a major surgical procedure. During the last few decades, less invasive endovascular procedures such as percutaneous transluminal renal artery angioplasty with stent placement have become available. At the same time, new antihypertensive and cardiovascular drugs have been developed, which may preclude revascularization, at least in some cases. The indications of each of these therapeutic options have changed over time. This review offers a temporal perspective on the course of technical and scientific advances and the accompanying change in clinical practice for the treatment of ischemic nephropathy. The latest randomized clinical trials, including the CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) trial, the largest on the subject, as well as a meta-analysis of these studies, have indicated that the best approach is medical therapy alone. There is evidence that revascularization brings no additional benefit, at least in low-risk and stable atherosclerotic renal artery stenosis. High-risk patients, especially those with recurrent flash pulmonary edema, could benefit from percutaneous transluminal renal artery angioplasty and stent placement, but there is no definitive evidence and the treatment choice should take into account the risks and potential benefits of the procedure.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerotic renal artery stenosis; ischemic nephropathy; percutaneous transluminal renal artery angioplasty; renovascular disease; stenting; treatment

Mesh:

Year:  2015        PMID: 25649878     DOI: 10.1053/j.ajkd.2014.11.026

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

1.  Risk factors associated with end-stage renal disease (ESRD) in patients with atherosclerotic renal artery stenosis: a nationwide population-based analysis.

Authors:  Tung-Min Yu; Chung-Shu Sun; Cheng-Li Lin; Chen-Yu Wang; Pi-Yi Chang; Che-Yi Chou; Ya-Wen Chuang; Bor-Jen Lee; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

2.  Successful Treatment of Resistant Hypertension by Means of Chronic Renal Artery Occlusion Revascularization in a Fragile Patient.

Authors:  Laura Spezia; Simone Perandini; Raffaele Augelli; Giovanni Puppini; Stefania Montemezzi
Journal:  Pol J Radiol       Date:  2016-11-10

3.  Prevalence and Vascular Distribution of Multiterritorial Atherosclerosis Among Community-Dwelling Adults in Southeast China.

Authors:  Yuesong Pan; Jing Jing; Xueli Cai; Zening Jin; Suying Wang; Yilong Wang; Chunlai Zeng; Xia Meng; Jiansong Ji; Long Li; Lingchun Lyu; Zhe Zhang; Lerong Mei; Hao Li; Shan Li; Tiemin Wei; Yongjun Wang
Journal:  JAMA Netw Open       Date:  2022-06-01

4.  Kidney-resident macrophages promote a proangiogenic environment in the normal and chronically ischemic mouse kidney.

Authors:  Amrutesh S Puranik; Irina A Leaf; Mark A Jensen; Ahmad F Hedayat; Ahmad Saad; Ki-Wook Kim; Abdulrahman M Saadalla; John R Woollard; Sonu Kashyap; Stephen C Textor; Joseph P Grande; Amir Lerman; Robert D Simari; Gwendalyn J Randolph; Jeremy S Duffield; Lilach O Lerman
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

5.  Renal Fibrosis Is Significantly Attenuated Following Targeted Disruption of Cd40 in Experimental Renal Ischemia.

Authors:  Shungang Zhang; Joshua D Breidenbach; Fatimah K Khalaf; Prabhatchandra R Dube; Chrysan J Mohammed; Apurva Lad; Stanislaw Stepkowski; Terry D Hinds; Sivarajan Kumarasamy; Andrew Kleinhenz; Jiang Tian; Deepak Malhotra; David J Kennedy; Christopher J Cooper; Steven T Haller
Journal:  J Am Heart Assoc       Date:  2020-03-21       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.